Since the NRG1-HER3 axis is implicated in resistance to HER2-targeted therapy, the impact of NRG1 levels was investigated in HER2-positive breast cancer patients instead of the whole TCGA breast cancer cohort. Here, ERBB3 is linked to breast cancer.